EP3790545A4 - Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie - Google Patents

Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie Download PDF

Info

Publication number
EP3790545A4
EP3790545A4 EP19742516.8A EP19742516A EP3790545A4 EP 3790545 A4 EP3790545 A4 EP 3790545A4 EP 19742516 A EP19742516 A EP 19742516A EP 3790545 A4 EP3790545 A4 EP 3790545A4
Authority
EP
European Patent Office
Prior art keywords
thalassemia
compositions
treatment
methods
sickle cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19742516.8A
Other languages
German (de)
English (en)
Other versions
EP3790545A1 (fr
Inventor
Yutaka Niihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emmaus Medical Inc
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Publication of EP3790545A1 publication Critical patent/EP3790545A1/fr
Publication of EP3790545A4 publication Critical patent/EP3790545A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19742516.8A 2019-07-17 2019-07-17 Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie Withdrawn EP3790545A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/000033 WO2021010937A1 (fr) 2019-07-17 2019-07-17 Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie

Publications (2)

Publication Number Publication Date
EP3790545A1 EP3790545A1 (fr) 2021-03-17
EP3790545A4 true EP3790545A4 (fr) 2021-07-28

Family

ID=74210735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19742516.8A Withdrawn EP3790545A4 (fr) 2019-07-17 2019-07-17 Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie

Country Status (2)

Country Link
EP (1) EP3790545A4 (fr)
WO (1) WO2021010937A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
WO2013095681A1 (fr) * 2011-12-19 2013-06-27 Emmaus Medical, Inc. Méthodes et compositions pour le traitement d'une diverticulose

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375994B1 (en) * 1999-08-20 2002-04-23 Sun Ten Laboratories, Inc. Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
CA2727088A1 (fr) * 2008-06-04 2009-12-10 Phenolics, Llc Formulations a enrobage enterique de polyethyleneglycol et d'un ou plusieurs acides amines solubles pour ingestion orale et leur assimilation amelioree
WO2013057592A2 (fr) 2011-09-14 2013-04-25 King Abdullah University Of Science And Technology Traitement de la drépanocytose
US10072067B2 (en) 2014-01-30 2018-09-11 Children's Hospital Medical Center Fetal hemoglobin for genetic correction of sickle cell disease
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
WO2013095681A1 (fr) * 2011-12-19 2013-06-27 Emmaus Medical, Inc. Méthodes et compositions pour le traitement d'une diverticulose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021010937A1 *

Also Published As

Publication number Publication date
EP3790545A1 (fr) 2021-03-17
WO2021010937A1 (fr) 2021-01-21

Similar Documents

Publication Publication Date Title
CA3243601A1 (en) Methods of making bempedoic acid and compositions of the same
EP4031152A4 (fr) Composés et compositions probiotiques pour le traitement de maladies et de troubles métaboliques
EP3863630A4 (fr) Compositions et procédés pour le traitement de la presbytie
EP4007764A4 (fr) Composés d'aminostérol ent-03 humain, compositions associées les comprenant, et leurs procédés d'utilisation
EP3818081A4 (fr) Compositions et méthodes pour le traitement de maladies ou de troubles liés aux inflammasomes
EP3846843A4 (fr) Compositions et procédés de traitement de maladie cardiaque
CA3266235A1 (fr) Compositions et procedes pour le traitement de maladies de la peau
EP3813872A4 (fr) Compositions pour le traitement d'affections cutanées
EP4048678A4 (fr) Composés et compositions pour le traitement de maladies parasitaires
EP4017873A4 (fr) Compositions et procédés pour le traitement de douleurs et de démangeaisons pathologiques
EP3914263A4 (fr) Procédés et compositions pour le traitement et la prévention de maladies et d'affections oculaires
EP3993833A4 (fr) Compositions et méthodes de traitement de maladies oculaires
EP4025258A4 (fr) Méthodes et compositions pour le traitement de la sclérose latérale amyotrophique
EP4054558A4 (fr) Méthodes et compositions pour la thérapie du diabète sucré de type 2
AU2019901644A0 (en) Compositions for the Treatment of Diseases and Conditions
HK40074157A (en) Compounds and compositions for the treatment of parasitic diseases
HK40063780A (en) Methods and compositions for the treatment of fabry disease
HK40109261A (en) Compositions and methods for treating sickle cell diseases
HK40068687A (en) Compositions and methods for the treatment of kras associated diseases or disorders
HK40081156A (en) Therapeutic cell compositions and methods for manufacture and uses thereof
HK40060506A (en) Compositions including cinnamic acid and methods of use thereof
HK40083234A (en) Modified cells and methods for the treatment of hemoglobinopathies
AU2019903606A0 (en) Method and Compositions for the Treatment of Disease
HK40062254A (en) Compositions and methods for treatment of diseases involving cxcl1 function
AU2018901624A0 (en) Compositions for the Treatment of Diseases and Conditions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190801

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20210625

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/365 20060101AFI20210621BHEP

Ipc: A61K 31/551 20060101ALI20210621BHEP

Ipc: A61K 45/06 20060101ALI20210621BHEP

Ipc: A61P 7/06 20060101ALI20210621BHEP

Ipc: A61K 31/198 20060101ALI20210621BHEP

Ipc: A61K 31/716 20060101ALI20210621BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240201